Diener H C
Department of Neurology, University of Essen, Germany.
Eur Neurol. 1994;34 Suppl 2:18-25. doi: 10.1159/000119528.
Acute drug therapy is the mainstay of treatment for migraine sufferers, with prophylaxis reserved for those with frequent or severe attacks. The majority of treatments have been in use for many years, although their value is often poorly documented due to a lack of well-controlled trials undertaken with defined diagnostic criteria and study end-points. Analgesics with anti-emetics, nonsteroidal anti-inflammatory drugs and ergot derivatives are used for acute treatment. Recently, the selective 5-HT1 receptor agonist sumatriptan has become available and been shown to have significant benefits over traditional therapies for the acute treatment of migraine. Beta-blockers, flunarizine and 5-HT2 antagonists have been used for prophylaxis, and although many patients report a reduction in attack frequency, breakthrough attacks still occur.
急性药物治疗是偏头痛患者治疗的主要手段，预防性治疗则适用于那些发作频繁或严重的患者。大多数治疗方法已经使用多年，尽管由于缺乏采用明确诊断标准和研究终点进行的严格对照试验，其疗效往往记录不充分。镇痛药加止吐药、非甾体抗炎药和麦角衍生物用于急性治疗。最近，选择性5-HT1受体激动剂舒马曲坦已上市，并已证明在偏头痛急性治疗方面比传统疗法有显著优势。β受体阻滞剂、氟桂利嗪和5-HT2拮抗剂已用于预防，尽管许多患者报告发作频率有所降低，但仍会出现突破性发作。
